These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 19110461)

  • 1. [How to prevent early postmenopausal fracture risk? Proposition of a strategy].
    Trémollieres F; Pouilles JM; Ribot C
    Gynecol Obstet Fertil; 2009 Jan; 37(1):50-6. PubMed ID: 19110461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.
    Hiligsmann M; Bruyère O; Reginster JY
    Bone; 2010 Feb; 46(2):440-6. PubMed ID: 19716940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
    Reginster JY; Felsenberg D; Boonen S; Diez-Perez A; Rizzoli R; Brandi ML; Spector TD; Brixen K; Goemaere S; Cormier C; Balogh A; Delmas PD; Meunier PJ
    Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
    Seeman E
    Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S17-20. PubMed ID: 16735841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strontium ranelate for osteoporosis?
    Drug Ther Bull; 2006 Apr; 44(4):29-32. PubMed ID: 16617933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoporosis: from early fracture prevention to better bone health with strontium ranelate.
    Cortet B
    Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv14-9. PubMed ID: 19783589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis.
    Adami S
    Bone; 2006 Feb; 38(2 Suppl 1):23-7. PubMed ID: 16434247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis.
    Hiligsmann M; Vanoverberghe M; Neuprez A; Bruyère O; Reginster JY
    Expert Rev Pharmacoecon Outcomes Res; 2010 Aug; 10(4):359-66. PubMed ID: 20715911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous broad protection against osteoporotic fractures with strontium ranelate.
    Ferrari S
    Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv20-4. PubMed ID: 19783590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age.
    Seeman E; Boonen S; Borgström F; Vellas B; Aquino JP; Semler J; Benhamou CL; Kaufman JM; Reginster JY
    Bone; 2010 Apr; 46(4):1038-42. PubMed ID: 20026265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
    Inderjeeth CA; Foo AC; Lai MM; Glendenning P
    Bone; 2009 May; 44(5):744-51. PubMed ID: 19130909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is treatment of early postmenopausal women with bisphosphonates justified?
    Epstein S
    Int J Clin Pract; 2007 Jun; 61(6):963-71. PubMed ID: 17504359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for treatment to prevent fragility fractures in postmenopausal women.
    Geusens P
    Best Pract Res Clin Rheumatol; 2009 Dec; 23(6):727-40. PubMed ID: 19945685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current approaches to the diagnosis and treatment of postmenopausal osteoporosis].
    Baranova IA
    Ter Arkh; 2009; 81(10):56-60. PubMed ID: 19947443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strontium ranelate: an increased bone quality leading to vertebral antifracture efficacy at all stages.
    Ortolani S; Vai S
    Bone; 2006 Feb; 38(2 Suppl 1):19-22. PubMed ID: 16455319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium].
    Uebelhart D; Frey D; Frey-Rindova P; Goerres G; Michel BA
    Z Rheumatol; 2003 Dec; 62(6):512-7. PubMed ID: 14685711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addressing and meeting the needs of osteoporotic patients with strontium ranelate: a review.
    Boonen S
    Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S21-7. PubMed ID: 16735842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strontium ranelate in the prevention of osteoporotic fractures.
    Reginster JY; Malaise O; Neuprez A; Bruyere O
    Int J Clin Pract; 2007 Feb; 61(2):324-8. PubMed ID: 17263720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
    Makras P; Hamdy NA; Zwinderman AH; Ballieux BE; Papapoulos SE
    Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained vertebral antifracture efficacy of oral anti-osteoporotic therapies in postmenopausal osteoporosis.
    Brandi ML
    Curr Med Res Opin; 2010 Nov; 26(11):2553-63. PubMed ID: 20858031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.